OPKO Health (NASDAQ:OPK) Announces Earnings Results, Beats Expectations By $0.07 EPS

OPKO Health (NASDAQ:OPK) released its earnings results on Monday. The biotechnology company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.07, FiscalAI reports. The firm had revenue of $163.58 million during the quarter, compared to analysts’ expectations of $131.23 million. OPKO Health had a negative net margin of 36.63% and a negative return on equity of 16.78%.

OPKO Health Trading Up 1.6%

NASDAQ:OPK traded up $0.02 during trading hours on Monday, reaching $1.24. 3,432,319 shares of the company were exchanged, compared to its average volume of 2,752,582. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.61 and a quick ratio of 3.17. The firm has a market cap of $936.31 million, a price-to-earnings ratio of -4.59 and a beta of 1.48. OPKO Health has a 52-week low of $0.98 and a 52-week high of $1.61. The stock has a 50 day simple moving average of $1.37 and a 200 day simple moving average of $1.26.

Institutional Trading of OPKO Health

Several institutional investors have recently made changes to their positions in OPK. StoneX Group Inc. purchased a new position in shares of OPKO Health in the 4th quarter worth $27,000. Zacks Investment Management acquired a new position in OPKO Health in the fourth quarter valued at $27,000. Cibc World Markets Corp purchased a new stake in OPKO Health during the fourth quarter valued at about $34,000. EP Wealth Advisors LLC purchased a new stake in OPKO Health during the fourth quarter valued at about $37,000. Finally, Norges Bank acquired a new stake in OPKO Health during the second quarter worth about $52,000. 64.63% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

OPK has been the subject of several analyst reports. Weiss Ratings upgraded OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Barrington Research downgraded OPKO Health from an “outperform” rating to a “market perform” rating in a research report on Wednesday, April 29th. Finally, Wall Street Zen raised OPKO Health from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Four equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus price target of $1.55.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.